A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Belimumab plus Standard of Care versus Placebo plus Standard of Care in Adult Subjects with Active Lupus Nephritis

Trial Profile

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Belimumab plus Standard of Care versus Placebo plus Standard of Care in Adult Subjects with Active Lupus Nephritis

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 08 Nov 2017

At a glance

  • Drugs Belimumab (Primary) ; Azathioprine; Cyclophosphamide; Mycophenolate; Steroids
  • Indications Lupus nephritis
  • Focus Therapeutic Use
  • Acronyms BLISS-LN
  • Sponsors GlaxoSmithKline; Human Genome Sciences
  • Most Recent Events

    • 20 Oct 2017 Planned End Date changed from 7 Feb 2020 to 5 Feb 2020.
    • 20 Oct 2017 Planned primary completion date changed from 26 Jul 2019 to 24 Jul 2019.
    • 20 Oct 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top